Based on these results and considering that biomarkers in ccRCC or TAMs are inadequate to comprehensively reflect tumor heterogeneity, we further combined RNF43 expression and CD163+ TAM infiltration to assess patient outcomes after surgery and exhibited superior accuracy than that of RNF43 or CD163 alone. This evidence concerns the gene CD163 and nonpapillary renal cell carcinoma.